Cure or Mirage? The High-Stakes Business of Reversing Diabetes

SHENZHEN, China – September 28, 2026

For families navigating the lifelong, relentless math of Type 1 diabetes, the word "cure" is a holy grail. It is a word that mainstream endocrinologists use with extreme caution, usually reserved for highly experimental islet cell transplants or cutting-edge immunosuppressive therapies. Yet, in a bold announcement emanating from southern China today, the Center for Integrative Medicine for Chronic Diseases at Shenzhen Hengsheng Hospital claims to have achieved exactly that.

The medical institution, a subsidiary of the healthcare conglomerate Fosun Health, announced the launch of an international program that it says has successfully reversed diabetes in thousands of patients. According to their release, over 1,000 individuals with Type 2 diabetes have seen an 80 percent complete medication discontinuation rate since 2018. More startlingly, the hospital claims that 30 out of 150 Type 1 diabetes patients managed by Professor An Chiying's team have successfully discontinued exogenous insulin entirely, achieving what the clinic defines as a "functional cure."

Marketed directly toward affluent family offices in the Arab Gulf states, Europe, and the United States, this initiative represents a massive commercial pivot for Chinese private healthcare. But a closer examination of the scientific data, clinical registries, and underlying business models reveals a troubling gap between the hospital's public relations triumph and the rigorous demands of evidence-based medicine.

The Anatomy of a "Functional Cure"

The claims emerging from the Shenzhen facility challenge the foundational consensus of global endocrinology. Type 1 diabetes is an autoimmune condition where the body's T-cells destroy the insulin-producing beta cells in the pancreas. Once clinical onset occurs, patients require lifelong exogenous insulin to survive.

Professor An Chiying emphasized in the press release that their real-world intervention outcomes are based on verifiable metrics, including glycated hemoglobin (HbA1c), time in range, C-peptide levels, and insulin dosages. The clinic defines its functional remission for Type 1 patients as maintaining an HbA1c level below 7 percent without the use of exogenous insulin.

However, independent medical experts point out a critical flaw in this framing: the conflation of a "cure" with a well-documented physiological phenomenon known as the "honeymoon phase."

When a patient is newly diagnosed with Type 1 diabetes and begins insulin therapy, the acute glucotoxicity in their body resolves. During this window, surviving beta cells often temporarily recover a fraction of their secretory capacity. This partial remission phase can last anywhere from a few months to two years. During this time, insulin needs plummet, and in select patients with high residual C-peptide levels, blood glucose can occasionally remain stable without injections.

Shenzhen Hengsheng Hospital's own patient cohorts explicitly target this exact demographic: newly diagnosed individuals within two years of onset who possess a fasting C-peptide level of 0.5 ng/mL or higher.

"Presenting the natural, temporary reprieve of the honeymoon phase as a therapeutic cure is clinically misleading," noted one independent academic endocrinologist specializing in beta-cell preservation. "If you withdraw insulin from a Type 1 diabetic without fundamentally halting the underlying autoimmune attack, you are placing them at imminent risk of Diabetic Ketoacidosis, which is a fatal metabolic crisis."

Furthermore, the hospital's claim of an 80 percent complete medication discontinuation rate in Type 2 diabetes patients vastly outpaces established global benchmarks. For context, the landmark UK DiRECT trial, which utilized intensive liquid meal replacements and significant weight loss, achieved a 46 percent remission rate at one year, which declined to 36 percent by year two. A real-world success rate of 80 percent suggests either unprecedented medical innovation or, more likely, severe patient selection bias and short-term follow-up.

Mass Spectrometry and Herbal Patches

If the physiological premise of the clinic's claims warrants skepticism, their clinical protocol demands equal scrutiny. The hospital asserts that it utilizes a world-leading mass spectrometry testing platform to identify the underlying causes of diabetes, followed by comprehensive interventions that allow patients to break free from medication.

Behind the high-tech jargon lies a blend of alternative functional medicine and traditional Chinese therapies. The mass spectrometry platform is primarily used to test for serum zonulin, a biomarker associated with intestinal barrier permeability, commonly referred to as "leaky gut syndrome." The clinic claims that restoring gut barrier integrity is the key to halting islet autoimmunity.

To achieve this, the medical team deploys a "5R" functional gut repair regimen, fecal microbiota transplantation (FMT), and high-dose orthomolecular supplements like zinc carnosine and L-glutamine. Most notably, the protocol relies on a proprietary herbal transdermal patch called the "Antang Tie," which is applied to the skin to allegedly regulate glycemic dynamics.

Despite the confident assertions of Professor An Chiying and her colleague Dr. Zou Zhenjun—who jointly released non-peer-reviewed "ultimate guides" to diabetes reversal on recent World Diabetes Days—there is a glaring void in the scientific literature. A comprehensive audit of the Chinese Clinical Trial Registry (ChiCTR) and ClinicalTrials.gov reveals zero registered clinical trials evaluating this integrative protocol for Type 1 diabetes reversal under their names.

Similarly, a search of indexed academic journals like PubMed and MEDLINE shows no published prospective data, randomized controlled trials, or even peer-reviewed case series documenting the 30 patients who supposedly achieved this functional cure. The hospital's claims exist entirely outside the ecosystem of global peer review.

Concierge Cures and Sovereign Wealth

To understand why a regional hospital is aggressively marketing unverified diabetes cures, one must look at the broader corporate strategy of its parent conglomerate. Fosun Health is a major player in China's private medical sector, and its leadership has been transparent about its ambition to transform the Greater Bay Area into a premier destination for international medical tourism, rivaling hubs in Singapore and Thailand.

This strategy is deeply intertwined with global geopolitics and the flow of private wealth. Earlier this year, Fosun International entered into a strategic partnership with the Abu Dhabi Investment Office, establishing a gateway to attract family offices and sovereign wealth into its healthcare ecosystem. By pitching exclusive chronic disease "reversal" programs to affluent families in the Gulf states, Europe, and the United States, the conglomerate is tapping into a highly lucrative, out-of-pocket VIP medical market.

The commercialization of this protocol is further institutionalized through Dr. Zou Zhenjun's private ventures. Corporate registry filings reveal that Dr. Zou is the founder of a health industry company that runs intensive, three-day "diabetes natural therapy health training camps." By integrating a commercial health coaching business with the licensed infrastructure of a Class-III hospital, the providers have created a seamless pipeline for monetizing alternative therapies.

"This is the luxury concierge model applied to chronic illness," explained a healthcare market analyst covering Asian medical tourism. "You are no longer just selling a hospital bed; you are selling an exclusive, high-ticket wellness retreat to foreign elites who have the capital to chase miracles."

For the global medical community, the aggressive promotion of these services raises profound ethical questions. The desperation that accompanies a chronic, life-altering diagnosis makes patients and their families uniquely vulnerable to the promise of a cure. While integrative medicine and lifestyle interventions undoubtedly play a vital role in managing metabolic health, packaging the transient physiology of early-stage autoimmune disease as a permanent, functional cure crosses a dangerous line. Until Shenzhen Hengsheng Hospital opens its data to rigorous, independent peer review, its international diabetes reversal program remains a triumph of marketing rather than a milestone of medicine.